-
How is Alzheimer's disease treated? Phase III trials of the AXS-05 are to be carried out
Time of Update: 2021-01-16
Alzheimer's disease is an aggressive neurodegenerative disease that is a common form of Alzheimer's disease characterized by cognitive decline and behavioral and psychological abnormalities, including restlessness.
-
New medicine for incurable depression! AXS-05 significantly improves depressive symptoms and impaired function
Time of Update: 2021-01-03
/> the right methafin part of AXS-05 is also a sigma-1 subjector astigtor, niacin acetylcholine ligand antagonist, serotonin, and dethyrene transporter inhibitor. AxS-05 amphetamine component improves the bio-utilization of right methafin
-
New medicine for incurable depression! AXS-05 (right methafen/aphedone release tablets) fast
Time of Update: 2020-12-19
-like regulator, which is a new mechanism of action, which means it functions differently from most depression drugs currently available. the right methafin part of AXS-05 is also a sigma-1 subjector astigtor, niacin acetylcholine ligand antagonist
-
Healing Alzheimer's! FDA grants AXS-05 breakthrough drug eligibility!
Time of Update: 2020-10-21
AXS-05 is a new, oral, proprietary NMDA subject antagonist with multi-mode activity and is currently being clinically developed to treat depression and other central nervous system (CNS) diseases.
-
As of 2020/05/28, a complete list of drugs for consistency evaluation has been published.
Time of Update: 2020-08-03
According to the pharmago visual analysis results, a total of 694 drugs (885 acceptance numbers) had passed consistency evaluations as of 2020/5/28.
-
Treating Alzheimer's (AD) is exciting! The FDA has awarded AXS-05 (right metafen/amphetamine transfer agent) breakthrough drug qualification!
Time of Update: 2020-07-19
AXS-05 is a new, oral, proprietary NMDA receptor antagonist with multi-modal activity and is currently in clinical development for the treatment of depression and other central nervous system (CNS) diseases.
-
AXS-05 approved by FDA for breakthrough therapy for Alzheimer's disorder
Time of Update: 2020-07-14
The results showed that AXS-05 could quickly improve restlessness in patients compared to placebos.
-
Axsome Therapeutics Innovative Therapy AXS-05 Awarded by fda for Breakthrough Therapy
Time of Update: 2020-06-10
Amphetamines improve the bioavailability of right meschafin, as well as norepinephrine and dopamine reuptake inhibitors, and niacin-type acetylcholine receptor antagonists.
-
The smoking cessation drug AXS-05 reaches its main endpoint in the course of smoking cessation
Time of Update: 2020-06-10
As a non-nicotine smoking cessation drug, AXS-05 is an innovative oral NMDA receptor antagonist.
-
Quickly improve symptoms! AXS-05 Treatment AD-Related Mania II/III Clinical End point
Time of Update: 2020-06-06
On April 27, local time, Axsome Therapeutics announced that its NMDA receptor antagonist AXS-05 had reached its primary endpoint in the 2/3 clinical trial ADVANCE-1 for Alzheimer's disease (AD) patients: rapid and significant improvement slower
-
AXS-05 Treatment of Alzheimer's Disease-Related Intensive Phase II/III Trial Accelerated!
Time of Update: 2020-05-31
Axsome accelerates completion of AXS-05 treatment of Alzheimer's-related radicals II/III trial!
-
ASTM International Standards Organization cancels all standard meetings scheduled for April
Time of Update: 2020-03-26
affected by the global new corona epidemic, ASTM, the American Materials and Testing Association, decided to cancel all on-site meetings scheduled for April , such as the ASTM Standards Meeting scheduled for March 29 to April 3
-
New medicine for depression! Axsome compound drug axs-05 (dextromethorphan / bupropion release
Time of Update: 2020-01-24
The dextromethorphan component of axs-05 is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, also known as glutamate receptor modulator, which is a new mechanism of action, which means that its effect is different from most depression drugs currently available.
-
Development of anti Ebola drug jk-05 by Sihuan pharmaceutical and Academy of Military Sciences
Time of Update: 2014-10-10
The new drug is one of about 15 experimental drugs against Ebola virus, which has been proved effective in cell culture and animal experiments in laboratories around the world
-
China's anti Ebola drug "jk-05" is expected to be put into Africa in batches
Time of Update: 2014-09-01
In recent days, the Ebola epidemic in West Africa seems to be showing no signs of improvement, and concerns about the global spread of the Ebola epidemic are increasing
-
"Jk-05", an anti Ebola drug of the Academy of Military Medical Sciences, was approved by the army as a special drug
Time of Update: 2014-08-29
Today, the reporter learned from the Academy of Military Medical Sciences that the drug "jk-05", developed by the Institute of microbial epidemiology of the Academy for Ebola virus
-
ASTM-D999 standard for simulated transport vibration table
Time of Update: 2009-06-04
Reference standard GB / t4857.1 method of marking all parts of packaging and transportation packages GB / y4857.2 handling of temperature and humidity of packaging
-
The Ministry of agriculture of Argentina estimates that the wheat output in 2004 / 05 will be 16 million tons
Time of Update: 2008-11-03
According to the Ministry of agriculture of Argentina, the wheat output in 2003 / 04 was 14.55 million tons.
-
Argentina's soybean harvest completed 13% in 2004 / 05
Time of Update: 2008-11-03
The U.S. Department of Agriculture estimates that the average soybean yield in Argentina in 2004 / 05 is 2.76 tons and the output is 39 million tons.
-
The shortage of grain supply and demand in 2004 / 05 will be relieved
Time of Update: 2008-11-03
The increase of output will effectively improve the supply capacity of domestic grain, so as to alleviate the current situation of tight domestic grain supply.
